Practice variation in re-resection for recurrent glioblastoma: A nationwide survey among Dutch neuro-oncology specialists

被引:3
|
作者
van Opijnen, Mark P. [1 ,2 ,3 ]
de Vos, Filip Y. F. [4 ]
Nabuurs, Rob J. A. [2 ,5 ]
Snijders, Tom J. [6 ]
Tewarie, Rishi D. S. Nandoe [2 ]
Taal, Walter [7 ]
Verhoeff, Joost J. C. [8 ]
van der Hoeven, Jacobus J. M. [9 ]
Broekman, Marike L. D. [2 ,3 ]
机构
[1] Haaglanden Med Ctr, Dept Neurosurg, Lijnbaan 32, NL-2512 VA The Hague, Netherlands
[2] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands
[3] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands
[4] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[5] Haga Teaching Hosp, Dept Neurosurg, The Hague, Netherlands
[6] Univ Med Ctr Utrecht, UMC Utrecht Brain Ctr, Dept Neurol & Neurosurg, Utrecht, Netherlands
[7] Erasmus MC Univ Med Ctr, Erasmus MC Canc Inst, Brain Tumor Ctr, Dept Neurol, Rotterdam, Netherlands
[8] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands
[9] Hartwig Med Fdn, Amsterdam, Netherlands
关键词
Glioblastoma; practice variation; recurrence; re-resection; survey; ADJUVANT TEMOZOLOMIDE; SURVIVAL; SURGERY; RADIOTHERAPY; PROGRESSION; CONCOMITANT;
D O I
10.1093/nop/npad016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Despite current best treatment options, a glioblastoma almost inevitably recurs after primary treatment. However, in the absence of clear evidence, current guidelines on recurrent glioblastoma are not well-defined. Re-resection is one of the possible treatment modalities, though it can be challenging to identify those patients who will benefit. Therefore, treatment decisions are made based on multidisciplinary discussions. This study aimed to investigate the current practice variation between neuro-oncology specialists. Methods In this nationwide study among Dutch neuro-oncology specialists, we surveyed possible practice variation. Via an online survey, 4 anonymized recurrent glioblastoma cases were presented to neurosurgeons, neuro-oncologists, medical oncologists, and radiation oncologists in The Netherlands using a standardized questionnaire on whether and why they would recommend a re-resection or not. The results were used to provide a qualitative analysis of the current practice in The Netherlands. Results The survey was filled out by 56 respondents, of which 15 (27%) were neurosurgeons, 26 (46%) neuro-oncologists, 2 (4%) medical oncologists, and 13 (23%) radiation oncologists. In 2 of the 4 cases, there appeared to be clinical equipoise. Overall, neurosurgeons tended to recommend re-resection more frequently compared to the other specialists. Neurosurgeons and radiation oncologists showed opposite recommendations in 2 cases. Conclusions This study showed that re-resection of recurrent glioblastoma is subject to practice variation both between and within neuro-oncology specialties. In the absence of unambiguous guidelines, we observed a relationship between preferred practice and specialty. Reduction of this practice variation is important; to achieve this, adequate prospective studies are essential.
引用
收藏
页码:360 / 369
页数:10
相关论文
共 5 条
  • [1] PRACTICE VARIATION OF STEROID DOSING AND TAPERING SCHEDULES AMONG THE NEURO-ONCOLOGY COMMUNITY
    Jessurun, Charissa
    Hulsbergen, Alexander
    Tewarie, Rishi Nandoe
    Smith, Timothy
    Broekman, Marike
    NEURO-ONCOLOGY, 2020, 22 : 85 - 85
  • [2] Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology
    Ranjan, Surabhi
    Skorupan, Nebojsa
    Ye, Xiaobu
    Sivakumar, Ananyaa
    Yankulina, Olga
    Kamson, David Olayinka
    Grossman, Stuart A.
    Dzaye, Omar
    Holdhoff, Matthias
    NEURO-ONCOLOGY PRACTICE, 2020, 7 (01) : 52 - 58
  • [3] Prognostic factors influencing survival following re-resection for isocitrate dehydrogenase (IDH) -wildtype glioblastoma multiforme-Data from a national neuro-oncology registry
    Hennessy, Maeve A.
    Coyne, Zachary L.
    O'Halloran, Philip J.
    Mullally, William
    Dablouk, Mohamed
    MacNally, Stephen
    Morris, Patrick G.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2022, 95 : 142 - 150
  • [4] Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
    N Beije
    J Kraan
    W Taal
    B van der Holt
    H M Oosterkamp
    A M Walenkamp
    L Beerepoot
    M Hanse
    M E van Linde
    A Otten
    R M Vernhout
    F Y F de Vos
    J W Gratama
    S Sleijfer
    M J van den Bent
    British Journal of Cancer, 2015, 113 : 226 - 231
  • [5] Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
    Beije, N.
    Kraan, J.
    Taal, W.
    van der Holt, B.
    Oosterkamp, H. M.
    Walenkamp, A. M.
    Beerepoot, L.
    Hanse, M.
    van Linde, M. E.
    Otten, A.
    Vernhout, R. M.
    de Vos, F. Y. F.
    Gratama, J. W.
    Sleijfer, S.
    van den Bent, M. J.
    BRITISH JOURNAL OF CANCER, 2015, 113 (02) : 226 - 231